Patent 11752190 was granted and assigned to Ra Pharmaceuticals on September, 2023 by the United States Patent and Trademark Office.
The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.